Sanofi secures $43 million government funding for zika vaccine development
Published on 27/09/16 at 09:17am
The US Department of Health and Human Services approved $43.18 million to fund Sanofi’s development of a zika vaccine, the company has announced.
The firm’s vaccine unit, Sanofi Pasteur, voiced its intention to develop a vaccine in collaboration with the government in June. The funding comes from the BioMedical Advanced Research and Development Authority (BARDA) and runs until June 2022 and will be used to pursue mid-stage trials beginning in 2018; an additional $130.45 is contracted for later-stage trials in the event that the data generated is positive.
Takeda recently secured $312 million from the same authority to work on a zika vaccine and GSK has also gone on record with an interest to join the development race.
Matt Fellows
- Login or register to post comments
- Printer-friendly version
Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches
Related content
